Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis

Aim To study the outcomes of patients presenting with locally advanced rectal cancers with distant metastasis (mLARC), treated with short course radiotherapy (SCRT). Method Between May 2012 and August 2015, 70 patients diagnosed with mLARC, treated with SCRT (25 Gy/5#) and three to six cycles of CAP...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2021-04, Vol.17 (2), p.e70-e76
Main Authors: Jain, Shanu, Engineer, Reena, Ostwal, Vikas, Ramaswamy, Anant, Chopra, Supriya, Desouza, Ashwin, Lewis, Shirley, Arya, Supreeta, Patil, Prachi, Saklani, Avanish
Format: Article
Language:English
Subjects:
Adult
Chemotherapy
CT (chemotherapy)
Disease control
Female
Humans
Male
Metastases
Metastasis
Middle Aged
mLARC (metastatic locally advanced rectal cancer)
Neoplasm Metastasis
Palliation
Patients
Radiation therapy
Rectal Neoplasms - pathology
Rectal Neoplasms - radiotherapy
Rectum
SCRT (short course radiotherapy)
Surgery
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim To study the outcomes of patients presenting with locally advanced rectal cancers with distant metastasis (mLARC), treated with short course radiotherapy (SCRT). Method Between May 2012 and August 2015, 70 patients diagnosed with mLARC, treated with SCRT (25 Gy/5#) and three to six cycles of CAPOX chemotherapy (CT), were assessed for surgical feasibility for the primary and metastatic sites. Results Sixty‐five patients could complete the planned SCRT and three to six cycles of CT. Response rate and disease control rate for the primary was 68% and 97%, respectively. Radiologically, CRM became free in 44 (72%) patients out of 61 initially involved. Fifty‐two (74%) were planned to receive treatment with a potentially curative intent and 18 (26%) with palliative intent. Of those treated with curative intent, 34 (65%) underwent primary tumor resection (PTR). Successful intervention for metastatic disease was done in 27 (52%) patients. At a median follow up of 43 months, the median overall survival (OS) for patients undergoing PTR was 36 months versus 12 months for those in which the tumor was still unresectable or had distant progression (P 
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.13305